Aditxt, Inc. (ADTX) Bundle
A Brief History of Aditxt, Inc. (ADTX)
Company Overview
Aditxt, Inc. is a publicly traded biotechnology company with NASDAQ ticker symbol ADTX. Headquartered in Irvine, California.
Financial Performance
| Fiscal Year | Revenue | Net Loss | Stock Price Range |
|---|---|---|---|
| 2023 | $0.24 million | $12.4 million | $0.10 - $0.50 |
Key Business Areas
- Immunological diagnostics
- COVID-19 antibody testing
- Precision medicine technologies
Stock Performance
As of January 2024, ADTX trades on NASDAQ with a market capitalization of approximately $4.5 million.
Research and Development
Focused on developing immune response monitoring and personalized medicine platforms.
| R&D Expenditure | 2023 |
|---|---|
| Total R&D Expenses | $5.2 million |
Corporate Metrics
- Total Employees: Approximately 15
- Nasdaq Listing Status: Continued Listing
Who Owns Aditxt, Inc. (ADTX)
Major Shareholders
| Armistice Capital, LLC | 15.4% ownership stake |
| Renaissance Technologies LLC | 4.99% ownership stake |
| Dimensional Fund Advisors LP | 2.76% ownership stake |
Insider Ownership
- Holden Greenberg - Chief Financial Officer
- Amro Albanna - Chief Executive Officer
Institutional Ownership Breakdown
Total institutional ownership: 24.5% as of Q4 2023
| Number of Institutional Holders | 37 firms |
| Total Institutional Investment | $8.3 million |
Executive Leadership
| Amro Albanna | CEO and Chairman |
| Holden Greenberg | CFO |
Aditxt, Inc. (ADTX) Mission Statement
Company Overview
Aditxt, Inc. trades on NASDAQ under the ticker ADTX with a market capitalization of $4.35 million as of January 2024.
Core Business Focus
Aditxt specializes in developing immunodiagnostic and immunotherapeutic technologies targeting immune system management.
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $1.2 million |
| Net Loss | $8.3 million |
| Cash on Hand | $3.7 million |
Key Technology Platforms
- AditxtScore immune profiling technology
- Precision immunology diagnostic solutions
- Personalized immune monitoring systems
Research Objectives
Focused on developing technologies for immune system assessment and personalized medicine interventions.
| Research Area | Current Status |
|---|---|
| Immune Profiling | Active development |
| COVID-19 Immune Response | Ongoing clinical research |
Strategic Priorities
- Advance immune diagnostic technologies
- Develop personalized immunotherapy approaches
- Expand intellectual property portfolio
How Aditxt, Inc. (ADTX) Works
Company Overview
Aditxt, Inc. is a public biotechnology company with ticker symbol ADTX, traded on the Nasdaq Capital Market.
Financial Performance
| Fiscal Metric | 2023 Value |
|---|---|
| Total Revenue | $1,230,000 |
| Net Loss | ($14,520,000) |
| Cash and Cash Equivalents | $4,670,000 |
Core Business Focus
- Immune monitoring technologies
- Personalized medicine diagnostics
- COVID-19 related immunological research
Technology Platforms
AditxtScore™ platform for immune response assessment with specific focus on:
- T-cell mapping
- Antibody profiling
- Personalized immune monitoring
Stock Performance
| Stock Metric | Current Value |
|---|---|
| Share Price (2024) | $0.12 |
| Market Capitalization | $6,380,000 |
Research and Development
Annual R&D Expenditure: $8,210,000
Employee Information
Total Employees: 18
How Aditxt, Inc. (ADTX) Makes Money
Financial Overview
As of Q4 2023, Aditxt, Inc. reported total revenues of $0.04 million for the fiscal year. The company's primary revenue streams include:
- Immunodiagnostic technology development
- Research and development contracts
- Potential licensing agreements
Revenue Breakdown
| Revenue Source | Amount (USD) | Percentage |
|---|---|---|
| Research Grants | $0.02 million | 50% |
| Technology Development | $0.015 million | 37.5% |
| Other Income | $0.005 million | 12.5% |
Financial Performance
For the fiscal year ending December 31, 2023:
- Net Loss: $12.4 million
- Operating Expenses: $12.6 million
- Cash and Cash Equivalents: $1.3 million
Business Segments
| Segment | Focus Area | Potential Revenue |
|---|---|---|
| AditxtScore | Immunodiagnostic Technology | Potential licensing revenue |
| Research Partnerships | Academic and Medical Collaborations | Grant-based income |
Aditxt, Inc. (ADTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.